Related Experiment Video
Updated: Aug 24, 2026

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
[Efficacy of cytoprotective agent Mexicor in urgent cardiology]
Insights
Mexicor improves outcomes for patients with unstable angina, myocardial infarction, and hypertensive crises. This cytoprotector reduces oxidant stress and enhances cardiac recovery when added to conventional treatments.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Ischemic heart disease (IHD) and arterial hypertension (AH) are significant cardiovascular conditions.
- Acute forms of IHD and AH crises require effective therapeutic interventions.
Purpose of the Study:
- To evaluate the efficacy of the cytoprotector mexicor as an adjunct therapy.
- To assess mexicor's impact on unstable angina (UA), acute myocardial infarction (MI), and hypertensive crises (HC).
Main Methods:
- An open randomized study involving 338 patients with acute IHD and AH.
- Patients received conventional therapy with or without mexicor (6-9 mg/kg/day).
- Evaluations included echocardiography, ECG, 24-h blood pressure monitoring, and lipid peroxidation (LPO) assessment.
Main Results:
- Mexicor diminished oxidant stress and improved left ventricular dysfunction.
- In MI patients, mexicor reduced akinetic zones and improved contractility.
- Mexicor enhanced angina stabilization in UA patients and normalized AP profiles in HC patients, halving HC recurrence.
Conclusions:
- Adjunctive mexicor therapy improves the clinical course of UA, MI, and HC.
- Mexicor reduces oxidant stress and accelerates cardiac recovery.
- The addition of mexicor aids in the normalization of central hemodynamics and cardiac rhythm variability.
Aim:
To study efficacy of cytoprotector mexicor in patients with unstable angina (UA), acute myocardial infarction (MI), hypertensive crises (HC) in combined therapy with conventional drugs.
Material And Methods:
An open randomized study included 338 patients with acute forms of ischemic heart disease (IHD) and arterial hypertension running with crises. Combined therapy of 20 patients with UA, 90 patients with MI and 43 patients with HC (study groups) was supplemented with mexicor in a dose 6-9 mg/kg/day. The control matched patients (20, 86 and 79 patients, respectively) received conventional treatment alone. The effects of the treatments were assessed by ultrasound investigation of the heart in M-, B- and Doppler modes, by ECG and arterial pressure 24-h monitoring, by activity of lipid peroxidation (LPO).
Results:
Adjuvant therapy of urgent cardiological conditions with mexicor diminished oxidant stress, left ventricular dysfunction. In MI patients mexicor promoted reduction of the akinesia zones, recovery of disturbed segmentary contractility. In UA patients mexicor contributed to more pronounced decrease in the frequency, duration and severity of myocardial ischemia, enhanced stabilization of angina. In HC patients mexicor promoted earlier normalization of a 24-h AP profile and variability of cardiac rhythm, recurrence rate of HC decreased 2-fold.
Conclusion:
The addition of mexicor to conventional therapy of UA, MI, HC improves clinical course of these diseases, reduces oxidant stress, accelerates recovery of cardiac contractility and left ventricular diastolic function, normalization of central hemodynamics.
Related Concept Videos
Cardiopulmonary Resuscitation IV: Pharmacological Management
Acute Coronary Syndrome IV: Interprofessional Care
Myocarditis III: Medical Management
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure Drugs: Inotropic Agents
Cardiomyopathy V: Interprofessional Care

